GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$122.42
+3.91%Oct 6, 2026, 17:30 UTC
The FDA advisory panel voted 7-2, with one abstention, that GRAIL, Inc.’s Galleri blood test offers more potential benefits than risks; the FDA is not bound by the recommendation.
Source:Oct 5, 2026, 20:01 UTC
GRAIL, Inc. announced it will present new data from the NHS-Galleri trial and the PATHFINDER 2 study evaluating its Galleri multi-cancer early detection test at the EDCC in Edinburgh and the ESMO Congress 2026 in Madrid.
Source:Sep 23, 2026, 11:30 UTC
An FDA advisory committee met to vote on whether the agency should approve Grail's Galleri multi-cancer blood test.
Sep 22, 2026, 19:00 UTC
MAHA Center, a nonprofit tied to HHS Secretary Robert F. Kennedy Jr., solicited corporate sponsorship payments of up to $300,000 for the Sept. 29 MAHA Summit in exchange for access to top U.S. health officials including Kennedy and CMS head Mehmet Oz.
Source:Sep 21, 2026, 17:17 UTC
The FDA staff released an executive summary document ahead of an advisory committee meeting concerning Grail Inc.'s Galleri multi-cancer early detection test.
Source:Sep 21, 2026, 16:44 UTC
US FDA staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares up 35% on Monday.
Sep 21, 2026, 15:28 UTC
Grail met with the U.S. Food and Drug Administration for premarket approval review of its multi-cancer blood test.
Source:Aug 13, 2026, 07:36 UTC
Bank of America Corp DE increased its stake in GRAIL, Inc. by 29.0% during the quarter, purchasing an additional 205,611 shares, according to its Form 13F filing.
Source:Aug 10, 2026, 17:30 UTC
The FDA's Molecular and Clinical Genetics Panel is scheduled to evaluate GRAIL Inc.'s Premarket Approval Application for its multi-cancer early detection test.
Source:Aug 7, 2026, 15:26 UTC
Grail announced on Friday that the U.S. FDA plans to hold an advisory committee meeting in September to review its multi-cancer screening test Galleri, causing its shares to rise 4% in morning trade.
Source:Aug 5, 2026, 20:02 UTC
GRAIL, Inc. reported its second quarter 2026 financial results, with Galleri test volume increasing 35% year-over-year to more than 61,000 and Galleri revenue growing 24% to $42.6 million.
Jul 24, 2026, 10:36 UTC
A class action lawsuit was filed against GRAIL, Inc. and its senior executives for securities fraud related to misrepresentations about trial results.
Jul 16, 2026, 13:00 UTC
GRAIL announced a collaboration with Priority Health to offer the Galleri multi-cancer early detection test to Priority Health's self-insured employer groups.
Source:Jun 25, 2026, 13:00 UTC
GRAIL completed a $110 million equity financing with Samsung affiliates.
Source:Jun 22, 2026, 21:57 UTC
A securities class action lawsuit has been filed against Grail, Inc. and its executives, with a lead plaintiff deadline of August 4, 2026.
Source:Jun 16, 2026, 23:00 UTC
A class action lawsuit was filed against Grail, Inc. alleging securities fraud for misleading investors about NHS-Galleri's potential to reduce late-stage cancers.
Jun 5, 2026, 21:53 UTC
A class action lawsuit was filed against Grail, Inc. on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026.
Source:Jun 1, 2026, 01:04 UTC
GRAIL presented new data at the American Society of Clinical Oncology annual meeting showing its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses.
Source:Jun 1, 2026, 00:00 UTC
Joshua Ofman was appointed Chief Executive Officer of GRAIL, Inc., effective June 1, 2026, with a base salary of $800,000 and an equity grant of RSUs valued at $2,000,000 vesting over four years.